French pharmaceutical Goliath Sanofi-Aventis SA on Friday expressed that the two patients dealt with its Multaq atrial fibrillation drug have experienced liver breakdown and need transplants, although no fundamental connection has been set up amid consuming the drug and the ailment.

Sanofi flanged a letter to healthcare suppliers in the U.S. regarding the case, group’s spokesman Jean-Marc Podvin conveyed to Dow Jones Newswires on Friday. Podvin added that Patient security is Sanofi's main concern. The group is also operational with European health establishments and in the nations where Multaq is agreed and those wherever it is presented for evaluation.

In a different statement on the website on Friday, the U.S. Food and Drug Administration expressed that it was warning healthcare experts and patients regarding cases of infrequent, but brutal liver injury, comprising 2 cases of sensitive liver collapse resulting in liver transplant in patients cured with the heart medication dronedarone (Multaq).

The firm wouldn't reveal in which nation the 2 cases of liver collapse occurred.

On its Multaq website, Sanofi-Aventis warns that patients with very harsh liver troubles and therefore should not consume the drug.